Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

INTRODUCTION: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). METHODS: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlson, Christopher, Siemers, Eric, Hake, Ann, Case, Michael, Hayduk, Roza, Suhy, Joyce, Oh, Joonmi, Barakos, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Neuroimaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879647/
https://www.ncbi.nlm.nih.gov/pubmed/27239538
http://dx.doi.org/10.1016/j.dadm.2016.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879647/
https://www.ncbi.nlm.nih.gov/pubmed/27239538
http://dx.doi.org/10.1016/j.dadm.2016.02.004

Ejemplares similares